Recent Updates
Recently added Catalysts

Bayer AG

BAYRYFDA catalysts, PDUFA dates & pipeline intelligence
$15.6
▼ -0.06 · -0.38%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full BAYRY financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
Volume
1.17 M
Value Traded
18.30 M
Short % Float
-
Days to Cover
1.0

Cash Data

Unlock BAYRY cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
-
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-
Total Shares
-
Float Shares
-
Insiders
-
Institutions
-

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every BAYRY catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

BAYRY Catalyst Timeline

Dated clinical, regulatory and corporate events for Bayer AG

Unlock the full BAYRY catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How BAYRY actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-11-09Sunharbo (asundexian) PDUFA Date ApprovedPDUFA
Unlock 14 more BAYRY historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
53
Drugs Scored
rNPV / MCap
Top Drug
Top 3%
Mid Cap
(rank 23 of 725)
Percentile Rank
Showing 91 of 570 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
Darolutamide Small MoleculesMarketedNCT04464226CancerApproved ACTIVE NOT_RECRUITING 774Jun 26, 2028
Darolutamide Small MoleculesNCT05794906Biochemically Recurrent Prostate CancerPhase 3 ACTIVE NOT_RECRUITING 1,013Mar 29, 2030
Darolutamide Small MoleculesNot countedNCT05676203Metastatic Hormone-sensitive Prostate CancerPhase 2 ACTIVE NOT_RECRUITING 727Dec 1, 2026
Darolutamide Small MoleculesNCT07450599High-risk Localized Prostate CancerPhase 2 RECRUITING 250Oct 15, 2030
Darolutamide Small MoleculesMarketedNCT07244341Metastatic Castration-resistant Prostate CancerApproved RECRUITING 120Nov 30, 2029
Darolutamide Small MoleculesMarketedNCT05826509Prostate CancerApproved ACTIVE NOT_RECRUITING 2,129Feb 1, 2031
Finerenone Small MoleculesMarketedNCT05196035Chronic Kidney DiseaseApproved ACTIVE NOT_RECRUITING 7,246May 10, 2027
Finerenone Small MoleculesNCT07192952Left Ventricular Systolic DysfunctionPhase 3 RECRUITING 228Dec 30, 2030
regorafenib Small MoleculesNCT06246643Solid Malignant TumorsPhase 2 ACTIVE NOT_RECRUITING 13Apr 27, 2028
VVD-133214 Small MoleculesNCT07811193Colorectal AdenocarcinomaPhase 2 RECRUITING 140Dec 31, 2030
OpCT-001 BiologicsNCT06789445Primary Photoreceptor DiseasePhase 1/2 RECRUITING 54Oct 1, 2030
BAY 3713372 Small MoleculesNCT06914128MTAP-deleted Solid TumorsPhase 1/2 RECRUITING 450Jun 18, 2029
BAY 3670549 Small MoleculesNCT07625215Atrial FibrillationPhase 2 RECRUITING 360May 16, 2030
Elinzanetant Small MoleculesNCT05587296Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast CancerPhase 3 ACTIVE NOT_RECRUITING 474Jun 5, 2028
Elinzanetant Small MoleculesNCT07762287Vasomotor Symptoms as a Sex Hormone-dependent Disorder in WomenPhase 1 RECRUITING 100Jan 22, 2027
Nurandociguat Small MoleculesNCT07431294Stable Coronary Artery DiseasePhase 1 NOT YET_RECRUITING 36May 7, 2027
BAY 3771249 Small MoleculesNCT07535112Advanced/Metastatic Colorectal AdenocarcinomaPhase 1 RECRUITING 130Jul 9, 2030
bemdaneprocel Cell TherapiesNCT06944522Parkinsons Disease (PD)Phase 3 RECRUITING 102Aug 1, 2034
Sevabertinib Small MoleculesMarketedNCT06452277Advanced Non-small Cell Lung Cancer, HER2 MutationApproved RECRUITING 444Jun 27, 2029
Sevabertinib Small MoleculesNCT06760819Advanced Solid TumorsPhase 2 RECRUITING 111Oct 26, 2029
BAY 3389934 Small MoleculesNCT06854640SepsisPhase 1 RECRUITING 36Jan 17, 2027
AB-1005 Gene TherapiesNCT06285643Parkinson DiseasePhase 2 ACTIVE NOT_RECRUITING 85Aug 31, 2028
BAY1213790 BiologicsCompletedNCT04523220End-stage Renal DiseasePhase 2 COMPLETED 704May 30, 2022
Fesomersen RNA-Based TherapiesCompletedNCT04534114End Stage Renal Disease Requiring HemodialysisPhase 2 COMPLETED 307May 12, 2022
Darolutamide Small MoleculesMarketedNCT02200614Prostate Cancer Non-MetastaticApproved COMPLETED 1,509Jun 14, 2021
Unlock the BAYRY pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every BAYRY program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Scroll for more · summaries link to the source press release
Unlock every BAYRY trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock BAYRY insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
No insider trades match the selected filters.
Unlock the full BAYRY insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in BAYRY for Q3 2026.
Unlock every fund holding BAYRY
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in BAYRY
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see BAYRY ownership
Insider and institutional ownership, quarter by quarter.

BAYRY Short Interest

Shares sold short, counted twice a month.

-
Short % of Float
of tradable shares sold short
112.8K
Shares Sold Short
-64.1% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
907.6K
Avg Daily Volume
the average used for days to cover
Unlock BAYRY short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock BAYRY option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live BAYRY option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock BAYRY options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How BAYRY ranks across every disease it competes in

Competitive Position is a premium feature
See how BAYRY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

BAYRY News

About Bayer AG

BIOPHARMAWATCH ELITE
Trade the next BAYRY catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime